Antimalarial and Antitumor Evaluation of Novel C-10 Non-Acetal Dimers of 10β-(2-Hydroxyethyl)deoxoartemisinin

Journal of Medicinal Chemistry

Volumn 47, Issue 5, 2004, Pages 1290-1298

  Jeyadevan, J Prince ^a   Bray, Patrick G ^b   Chadwick, James ^a   Mercer, Amy E ^a   Byrne, Aoife ^a   Ward, Stephen A ^b   Park, B Kevin ^a   Williams, Dominic P ^a   Cosstick, Rick ^a   Davies, Jill ^b   Higson, Adrian P ^c   Irving, Ed ^c   Posner, Gary H ^d   O'Neill, Paul M ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^c Ultrafine UFC Ltd   (United Kingdom)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

10BETA (2 HYDROXYETHYL)DEOXOARTEMISININ; ALCOHOL; ARTEMISININ DERIVATIVE; DIMER; DOXORUBICIN; PHOSPHATE; UNCLASSIFIED DRUG;

ANTIMALARIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIMERIZATION; DRUG ACTIVITY; DRUG POTENCY; GROWTH INHIBITION; HUMAN; HUMAN CELL; MALARIA; PLASMODIUM FALCIPARUM; STRAIN DIFFERENCE;

ACETALS; ANIMALS; ANTIMALARIALS; ANTINEOPLASTIC AGENTS; ARTEMISININS; CELL LINE, TUMOR; DIMERIZATION; DRUG RESISTANCE; DRUG SCREENING ASSAYS, ANTITUMOR; FLOW CYTOMETRY; HUMANS; PLASMODIUM FALCIPARUM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 10744231930     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030974c     Document Type: Article

References (47)

1. Avery, M. A. Current Progress in the Chemistry, Medicinal Chemistry and Drug Design of Artemisinin Based Antimalarials. Curr. Pharm. Des. 1999, 5, 101-138.
2. (a) Haynes, R. K.; Vonwiller, S. C. The Behaviour of Qinghaosu (Artemisinin) in the Presence of Heme Iron (II) and (III). Tetrahedron Lett. 1996, 37, 253-256.
3. (b) Haynes, R. K.; Vonwiller, S. C. The Behaviour of Qinghaosu (Artemisinin) in the Presence of Non-Heme Iron (II) and (III) Tetrahedron Lett. 1996, 37, 257-260. Posner, G. H.; Wang, D.; Cumming, J. N.; Oh, C. H.; French, A. N.; Bodley, A. L.; Shapiro, T. A. Further Evidence Supporting the Importance of and Restrictions on a Carbon Centred Radical for High Antimalarial Activity of 1,2,4 Trioxanes Like Artemisinin. J. Med. Chem. 1995, 38, 2273-2275.
4. (b) Haynes, R. K.; Vonwiller, S. C. The Behaviour of Qinghaosu (Artemisinin) in the Presence of Non-Heme Iron (II) and (III) Tetrahedron Lett. 1996, 37, 257-260. Posner, G. H.; Wang, D.; Cumming, J. N.; Oh, C. H.; French, A. N.; Bodley, A. L.; Shapiro, T. A. Further Evidence Supporting the Importance of and Restrictions on a Carbon Centred Radical for High Antimalarial Activity of 1,2,4 Trioxanes Like Artemisinin. J. Med. Chem. 1995, 38, 2273-2275.
5. For examples of biomimetic Fe(II) chemistry and EPR studies of peroxides, see the following. (c) Butler, A. R.; Gilbert, B. C.; Hulme, P.; Irvine, L. R. ; Renton, L.; Whitwood, A. C. EPR Evidence for the Involvement of Free Radicals in the Iron-Catalysed Decomposition of Qinghaosu (Artemisinin) and Some Derivatives; Antimalarial Action of Some Polycyclic Endoperoxides. Free Radical Res. 1998, 28, 471-476.
6. (d) O'Neill, P. M.; Bishop, L. P.; Searle, N. L.; Maggs, J. L.; Bray, P. G.; Ward, S. A.; Park, B. K. The Biomimetic Iron-Mediated Degradation of Arteflene (Ro-42-1611), an Endoperoxide Antimalarial: Implications for the Mechanism of Antimalarial Activity. Tetrahedron Lett. 1997, 38, 4263-4266.
7. (a) Woerdenbag, H. J.; Moskal, T. A.; Pras, N.; Maringle, T. M.; El-Feraly, F. S.; Kampinga, H. H.; Konings, A. W. T. Cytotoxicity of Artemisinin-Related Endoperoxides to Ehrlich Ascites Tumour. J. Nat. Prod. 1993, 56, 849.
8. (b) Galal, A. M.; Ahmad, M. S.; El-Feraly, F. S. Preparation and Characterization of a New Artemisinin-Derived Dimer. J. Nat. Prod. 1996, 59, 917-920.
9. Haynes, R. K.; Lam, W. L.; Hsiao, W. W. L.; Chan, H. W.; Cheung, M. K.; Tsang, H. W.; Greif, G.; Schmuck, G.; Lerchen, H. G. Artemisinin Derivatives Bearing DNA Intercalating and Binding Groups Displaying Anticancer Activity. 98305593.0, July 14, 1998; Europe; International (PCT) PCT/GB99/02276, July 1999.
10. Wu, J.-M.; Shan, F.; Wu, G.-S.; Li, Y.; Ding, J.; Xiao, D.; Han, J.-X.; Atassi, G.; Leonce, S.; Caignard, D.-H.; Renard, P. Synthesis and Cytotoxicity of Artemisinin Derivatives Containing Cyanoarylmethyl Group. Eur. J. Med. Chem. 2001, 36, 469-479.
11. Chen, Y.-H.; Liu, J.-X.; Lown, J. W. Design, Synthesis and Evaluation of Novel Bismustard Cross-Linked Lexitropsins. Biol. Med. Chem. Lett. 1995, 5, 2223-2228.
12. Droegmuller, M.; Flessner, T.; Jautelat, R.; Scholz, U.; Winterfeldt, E. Synthesis of Cephalostation Analogues by Symmetrical and Non Symmetrical Routes. Eur. J. Org. Chem. 1998, 2811-2831.
13. Borman, S. Higher Yield Synthetic Route to Cyclic Enediynes Developed. Chem. Eng. News 1995, 73 (35), 28-30.
14. Ma, X.; Yu, B.; Hui, Y.; Miao, Z.; Ding, H. Synthesis of OSW-1 Analogues and a Dimer and Their Antitumor Activities. Biol. Med. Chem. Lett. 2001, 11, 2153-2156.
15. Posner, G. H.; Ploypradith, P.; Hapangama, W.; Wang, D.; Cumming, J. N.; Dolan, P.; Kensler, T. W.; Klinedinst, D.; Shapiro, T. A.; Zheng, Q. Y.; Murray, C. K.; Pilkington, L. G.; Jayasinghe, L. R.; Bray, J. F.; Daughenbaugh, R. Trioxane Dimers Have Potent Antimalarial, Antiproliferative, and Antitumor Activities in Vitro. Bioorg. Med. Chem. 1997, 5, 1257-1265.
16. Zheng, Q. Y.; Darbie, L. G. (Hauser Inc.) Artemisinin Dimer Compounds Having Anticancer Activity. U.S. Patent 5,677,468, 1997.
17. (a) Posner, G. H.; Ploypradith, P.; Parker, M. H.; O'Dowd, H.; Woo, S.-H.; Northrop, J.; Krasavin, M.; Dolan, P.; Kensler, T. W.; Xie, S.; Shapiro, T. A. Antimalarial, Antiproliferative, and Antitumor Activities of Artemisinin Derived, Chemically Robust, Trioxane Dimers. J. Med. Chem. 1999, 42, 4275-4280.
18. (b) Posner, G. H.; Park, I.-H.; Sur, S.; McRiner, A. J.; Borstnik, K.; Xie, S.; Shapiro, T. A. Orally Active, Antimalarial, Anticancer, Artemisinin Derived Trioxane Dimers with High Stability and Efficacy. J. Med. Chem. 2003, 46, 1060-1065.
19. (c) Jung, M.; Lee, S.; Ham, J.; Lee, K.; Kim, H.; Kim, S. K. Antitumor Activity of Novel Deoxoartemisinin Monomers, Dimers, and Trimer. J. Med. Chem. 2003, 46, 987-994.
20. (a) Tomasz, M.; Palom, Y. The Mitomycin Bioreductive Antitumor Agents: Cross-Linking and Alkylation of DNA as the Molecular Basis of Their Activity. Pharmacol. Ther. 1997, 76, 73-87.
21. (b) Williams, R. M.; Rollins, S. B.; Judd, T. C. Synthesis of the First Photo-Triggered Pro-mitosene Based on FR-900482. Tetrahedron 2000, 56, 521-532.
22. (a) Jung, M.; Elsohly, H. N.; McChesney, J. D. A Concise Synthesis of Novel C-13 Functionalized Deoxoartemisinins. Synlett 1993, 43-44.
23. (b) O'Neill, P. M.; Searle, N. L.; Wan, K.-W.; Storr, R. C.; Maggs, J. L.; Ward, S. A.; Raynes, K.; Park, B. K. Novel, Potent, Semi-synthetic Antimalarial Carba Analogues of the First Generation 1,2,4-Trioxane Artemether. J. Med. Chem. 1999, 42, 5487-5493.
24. (a) Posner, G. H.; Parker, M. H.; Northrop, J.; Elias, J. S.; Ploypradith, P.; Xie, S. J.; Shapiro, T. A. Orally Active, Hydrolytically Stable, Semisynthetic, Antimalarial Trioxanes in the Artemisinin Family. J. Med. Chem. 1999, 42, 300-304.
25. (b) O'Dowd, H.; Ploypradith, P.; Xie, S. J.; Shapiro, T. A.; Posner, G. H. Antimalarial Artemisinin Analogs. Synthesis via Chemoselective C-C Bond Formation and Preliminary Biological Evaluation. Tetrahedron 1999, 55, 3625-3636.
26. (c) Chorki, F.; Crousse, B.; Bonnet-Delpon, D.; Bégué, J. P.; Brigaud, T.; Portella, C. C-10-Fluorinated Derivatives of Dihydroartemisinin: Difluoromethylene Ketones. Tetrahedron Lett. 2001, 42, 1487-1489.
27. Pu, Y.-M.; Ziffer, H. Synthesis and Antimalarial Activities of 12β-Allyldeoxoartemisinin and Its Derivatives. J. Med. Chem. 1995, 38, 613-616.
28. Hindley, S.; Ward, S. A.; Storr, R. C.; Searle, N. L.; Bray, P. G.; Park, B. K.; Davies, J.; O'Neill, P. M. Mechanism-Based Design of Parasite Targeted Artemisinin Derivatives: Synthesis and Antimalarial Activity of New Diamine Containing Analogues. J. Med. Chem. 2002, 45, 1052-1063.
29. Hatakeyama, S.; Mori, H.; Kitano, K.; Yamada, H.; Nishizawa, M. Efficient Reductive Etherification of Carbonyl-Compounds with Alkoxytrimethylsilanes. Tetrahedron Lett. 1994, 35, 4367-4370.
30. Boyd, M. R.; Paull, K. D. Some Practical Considerations and Applications of the National Cancer Institute in Vitro Drug Discovery Program. Drug Dev. Res. 1995, 34, 91-109.
31. (a) May, W. S.; Cuatrecasas, P. Transferrin Receptor: Its Biological Significance. J Membr. Biol. 1985, 88, 205-215.
32. (b) Gatter, K.; Brown, G.; Trowbridge, I. S.; Woolston, R.-E.; Mason, D. Y. Transferrin Receptors in Human Tissues: Their Distribution and Possible Clinical Relevance. J Clin. Pathol. 1983, 36, 539-545.
33. (a) Chitambar, C. R.; Wereley, J. P. Transferrin Receptor-Dependent and Independent Iron Transport in Gallium-Resistant Human Lymphoid Leukemic Cells. Blood 1998, 91, 4686-4693.
34. (b) Tanaka, T.; Kaneo, Y.; Miyashita, M. Intracellular Disposition and Cytotoxicity of Transferrin Mitomycin C Conjugate in HL60 Cells as a Receptor-Mediated Drug Targeting System. Biol. Pharm. Bull. 1998, 21, 147-152.
35. (c) Sarti, P.; Ginobbi, P.; Dagostino, I. Liposomal Targeting of Leukaemia HL60 Cells Induced by Transferrin-Receptor Endocytosis. Biotechnol. Appl. Biochem. 1996, 24, 269-276.
36. Beyer, U.; Roth, T.; Schumacher, P.; Maier, G.; Unold, A.; Frahm, A. W.; Fiebig, H. H.; Unger, C.; Kratz, F. Synthesis and in Vitro Efficacy of Transferrin Conjugates of the Anticancer Drug Chlorambucil. J. Med. Chem. 1998, 41, 2701-2708.
37. Moss, D.; Hibbs, A. R.; Stenzel, D.; Powell, L. W.; Halliday, J. W. The Endocytic Pathway for H-Ferritin Established in Live Molt-4 Cells by Laser-Scanning Confocal Microscopy. Br. J. Haematol. 1994, 88, 746-753.
38. Seki, M.; Iwakawa, J.; Cheng, H.; Cheng, P. W. P53 and PTEN/MMAC1/TEP1 Gene Therapy of Human Prostate PC-3 Carcinoma Xenograft, Using Transferrin-Facilitated Lipofection Gene Delivery Strategy. Hum. Gene Ther. 2002, 13, 761-773.
39. Shinohara, H.; Fan, D.; Ozawa, S.; Yano, S. J.; Van Arsdell, M.; Viner, J. L.; Beers, R.; Pastan, I.; Fidler, I. J. Site-Specific Expression of Transferrin Receptor by Human Colon Cancer Cells Directly Correlates with Eradication by Antitransferrin Recombinant Immunotoxin. Int. J. Oncol. 2000, 17, 643-651.
40. (a) Ikuta, K.; Fujimoto, Y.; Suzuki, Y.; Tanaka, K.; Saito, H.; Ohhira, M.; Sasaki, K.; Kohgo, Y. Overexpression of Hemochromatosis Protein, HFE, Alters Transferrin Recycling Process in Human Hepatoma Cells. Biochim. Biophys. Acta 2000, 1496, 221-231.
41. (b) Kawabata, H.; Nakamaki, T.; Ikonomi, P.; Smith, R. D.; Germain, R. S.; Koeffier, H. P. Expression of Transferrin Receptor 2 in Normal and Neoplastic Hematopoietic Cells. Blood 2001, 98, 2714-2719.
42. (a) Hockenbery, D. M.; Oltvai, Z. N.; Yin, X.-M.; et al. Bcl-2 functions in an Antioxidant Pathway To Prevent Apoptosis. Cell 1993, 75, 241-251.
43. (b) Fernandes, R. S.; Cotter, T. G. Apoptosis or Necrosis: Intracellular Levels of Glutathione Influence Mode of Cell Death. Biochem Pharmacol. 1994, 48, 675-681.
44. Singh, N. P.; Lai, H Selective Toxicity of Dihydroartemisinin and Holotransferrin toward Human Breast Cancer Cells. Life Sci. 2001, 70, 49-56.
45. Jensen, J. B.; Trager, W. Plasmodium falciparum in Culture. Use of Outdated Erythrocytes and Description of the Candle Jar Method. J. Parasitol. 1977, 63, 883-886.
46. Desjardins, R. E.; Canfield, J.; Haynes, D.; Chulay, D. J. Quantitative Assessment of Antimalarial Activity in Vitro by a Semi-automated Microdilution Technique. Antimicrob. Agents Chemother. 1979, 16, 710-718.
47. Nicoletti, I.; Migliorati, G.; Paggliacci, M. C.; Grigani, F.; Riccardi, C. A Rapid and Simple Method for Measuring Thymocyte Apoptosis by Propidium Iodide Staining and Flow Cytometry. J. Immunol. Methods 1991, 139, 271-279.